Published in Obesity and Diabetes Week, July 19th, 2004
The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Glucophage XR Tablets of Bristol Myers Squibb Company.
Total market sales for the Metformin Extended-release formulation are $363 million. The approval was granted after Barr Laboratories, Inc., a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.